Symbols / RNA Stock $12.55 -2.71% Atrium Therapeutics, Inc.
RNA (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Ratings
Current target
$12.55
Low
$25.00
High
$25.00
Mean
$25.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-11 | init | Wells Fargo | — → Overweight | $25 |
| 2025-11-11 | main | Chardan Capital | Neutral → Neutral | $72 |
| 2025-10-29 | down | TD Cowen | Buy → Hold | $74 |
| 2025-10-28 | down | Chardan Capital | Buy → Neutral | $72 |
| 2025-10-28 | down | RBC Capital | Outperform → Sector Perform | $72 |
| 2025-10-27 | down | Citigroup | Buy → Neutral | $72 |
| 2025-10-27 | down | Leerink Partners | Outperform → Market Perform | $72 |
| 2025-10-27 | down | Raymond James | Strong Buy → Market Perform | — |
| 2025-10-27 | down | Bernstein | Outperform → Market Perform | $72 |
| 2025-10-27 | down | Needham | Buy → Hold | $65 |
| 2025-10-27 | down | HC Wainwright & Co. | Buy → Neutral | $72 |
| 2025-09-22 | main | Evercore ISI Group | Outperform → Outperform | $65 |
| 2025-09-17 | init | Roth Capital | — → Buy | $62 |
| 2025-09-15 | main | B of A Securities | Buy → Buy | $65 |
| 2025-09-12 | main | HC Wainwright & Co. | Buy → Buy | $87 |
| 2025-09-10 | main | Needham | Buy → Buy | $65 |
| 2025-09-10 | main | Chardan Capital | Buy → Buy | $75 |
| 2025-08-08 | main | Wells Fargo | Overweight → Overweight | $75 |
| 2025-08-08 | main | Barclays | Overweight → Overweight | $62 |
| 2025-08-08 | main | Chardan Capital | Buy → Buy | $75 |
News
RSS: Latest RNA news- BlackRock (NASDAQ: RNA) reports 5.2% stake — 892,387 shares - Stock Titan Mon, 27 Apr 2026 20
- Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders - PR Newswire Mon, 23 Feb 2026 08
- $RNA stock is down 80% today. Here's what we see in our data. | RNA Stock News - Quiver Quantitative Fri, 27 Feb 2026 08
- Atrium Therapeutics Stock Pre-Market (-4.5%): Launch as Public Company Post-Spin-Off - Trefis Sat, 28 Feb 2026 08
- Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger - Yahoo Finance Sun, 02 Nov 2025 07
- Avidity Biosciences Announces Expected Record Date for Spin-Off - PR Newswire Mon, 02 Feb 2026 08
- Atrium offers stock awards to 7 new hires under Nasdaq rule - Stock Titan ue, 21 Apr 2026 02
- Avidity Biosciences (RNA) Soars to All-Time High on Looming $12-Billion Merger with Novartis - Yahoo Finance ue, 28 Oct 2025 07
- $RNA stock is up 42% today. Here's what we see in our data. - Quiver Quantitative Mon, 27 Oct 2025 07
- Atrium Therapeutics (RNA) CSO granted RSUs and 60,000 stock options in Form 4 - Stock Titan Wed, 22 Apr 2026 21
- Avidity Biosciences Announces Proposed Public Offering of Common Stock - PR Newswire Wed, 10 Sep 2025 07
- Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger - Yahoo Finance Fri, 27 Feb 2026 08
- Atrium Therapeutics (RNA) CFO awarded 30,000 RSUs and 60,000 stock options - Stock Titan Wed, 22 Apr 2026 21
- RNA Stock Moves More Than 30% in a Week: What's Driving This Rally? - Yahoo Finance Mon, 25 Aug 2025 07
- Atrium Therapeutics grants RSUs and options to executive | RNA Insider Trading - Stock Titan Wed, 22 Apr 2026 21
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Revenue |
|
18.62
+70.85%
|
10.90
+11.60%
|
9.76
|
| Operating Revenue |
|
18.62
+70.85%
|
10.90
+11.60%
|
9.76
|
| Operating Expense |
|
95.43
+295.74%
|
24.11
+49.32%
|
16.15
|
| Research And Development |
|
53.76
+179.99%
|
19.20
+51.73%
|
12.65
|
| Selling General And Administration |
|
41.68
+747.76%
|
4.92
+40.58%
|
3.50
|
| General And Administrative Expense |
|
41.68
+747.76%
|
4.92
+40.58%
|
3.50
|
| Other Gand A |
|
41.68
+747.76%
|
4.92
+40.58%
|
3.50
|
| Total Expenses |
|
95.43
+295.74%
|
24.11
+49.32%
|
16.15
|
| Operating Income |
|
-76.81
-481.13%
|
-13.22
-106.98%
|
-6.39
|
| Total Operating Income As Reported |
|
-76.81
-481.13%
|
-13.22
-106.98%
|
-6.39
|
| EBITDA |
|
-76.49
-486.32%
|
-13.05
-108.80%
|
-6.25
|
| Normalized EBITDA |
|
-76.49
-486.32%
|
-13.05
-108.80%
|
-6.25
|
| Reconciled Depreciation |
|
0.32
+87.79%
|
0.17
+24.64%
|
0.14
|
| EBIT |
|
-76.81
-481.13%
|
-13.22
-106.98%
|
-6.39
|
| Net Income |
|
-76.68
-205.25%
|
-25.12
-293.45%
|
-6.38
|
| Pretax Income |
|
-76.83
-481.31%
|
-13.22
-106.99%
|
-6.38
|
| Other Income Expense |
|
-0.01
-700.00%
|
0.00
+100.00%
|
0.00
|
| Other Non Operating Income Expenses |
|
-0.01
-700.00%
|
0.00
+100.00%
|
0.00
|
| Tax Provision |
|
-0.14
-101.19%
|
11.91
|
0.00
|
| Tax Rate For Calcs |
|
0.00
-98.57%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-76.68
-205.25%
|
-25.12
-293.45%
|
-6.38
|
| Net Income From Continuing Operation Net Minority Interest |
|
-76.68
-205.25%
|
-25.12
-293.45%
|
-6.38
|
| Net Income From Continuing And Discontinued Operation |
|
-76.68
-205.25%
|
-25.12
-293.45%
|
-6.38
|
| Net Income Continuous Operations |
|
-76.68
-205.25%
|
-25.12
-293.45%
|
-6.38
|
| Normalized Income |
|
-76.68
-205.25%
|
-25.12
-293.45%
|
-6.38
|
| Net Income Common Stockholders |
|
-76.68
-205.25%
|
-25.12
-293.45%
|
-6.38
|
| Diluted EPS |
|
-4.48
-205.19%
|
-1.47
-293.45%
|
-0.37
|
| Basic EPS |
|
-4.48
-205.19%
|
-1.47
-293.45%
|
-0.37
|
| Basic Average Shares |
|
17.11
+0.00%
|
17.11
+0.00%
|
17.11
|
| Diluted Average Shares |
|
17.11
-0.06%
|
17.12
+0.00%
|
17.12
|
| Diluted NI Availto Com Stockholders |
|
-76.68
-205.25%
|
-25.12
-293.45%
|
-6.38
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Assets |
|
278.35
+3773.55%
|
7.19
-30.19%
|
10.29
|
| Current Assets |
|
272.85
+56389.65%
|
0.48
-43.57%
|
0.86
|
| Cash Cash Equivalents And Short Term Investments |
|
270.00
|
—
|
—
|
| Cash And Cash Equivalents |
|
270.00
|
—
|
—
|
| Receivables |
|
—
|
0.00
-100.00%
|
0.75
|
| Accounts Receivable |
|
—
|
0.00
-100.00%
|
0.75
|
| Prepaid Assets |
|
1.53
+217.81%
|
0.48
+360.00%
|
0.10
|
| Other Current Assets |
|
1.31
|
—
|
—
|
| Total Non Current Assets |
|
5.51
-17.83%
|
6.70
-28.97%
|
9.44
|
| Net PPE |
|
5.51
-17.83%
|
6.70
-28.97%
|
9.44
|
| Gross PPE |
|
8.35
+5.23%
|
7.94
-23.11%
|
10.32
|
| Accumulated Depreciation |
|
-2.84
-130.47%
|
-1.23
-39.44%
|
-0.89
|
| Properties |
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
1.77
|
0.00
|
—
|
| Other Properties |
|
6.58
-13.96%
|
7.65
-23.77%
|
10.03
|
| Leases |
|
0.00
-100.00%
|
0.29
+0.00%
|
0.29
|
| Total Liabilities Net Minority Interest |
|
71.07
+4.06%
|
68.29
-15.59%
|
80.91
|
| Current Liabilities |
|
41.80
+55.96%
|
26.80
-20.71%
|
33.80
|
| Payables And Accrued Expenses |
|
13.34
+673.51%
|
1.73
+49.61%
|
1.15
|
| Payables |
|
4.40
+726.69%
|
0.53
+6.83%
|
0.50
|
| Accounts Payable |
|
4.40
+726.69%
|
0.53
+6.83%
|
0.50
|
| Current Accrued Expenses |
|
8.95
+649.79%
|
1.19
+82.14%
|
0.66
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
3.15
+1179.27%
|
0.25
-70.99%
|
0.85
|
| Current Debt And Capital Lease Obligation |
|
3.67
-4.47%
|
3.84
+5.63%
|
3.64
|
| Current Capital Lease Obligation |
|
3.67
-4.47%
|
3.84
+5.63%
|
3.64
|
| Current Deferred Liabilities |
|
21.64
+3.11%
|
20.99
-25.47%
|
28.16
|
| Current Deferred Revenue |
|
21.64
+3.11%
|
20.99
-25.47%
|
28.16
|
| Total Non Current Liabilities Net Minority Interest |
|
29.27
-29.47%
|
41.49
-11.93%
|
47.11
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
2.96
-52.41%
|
6.21
|
| Long Term Capital Lease Obligation |
|
—
|
2.96
-52.41%
|
6.21
|
| Non Current Deferred Liabilities |
|
28.69
-24.42%
|
37.96
-7.18%
|
40.90
|
| Non Current Deferred Revenue |
|
28.69
-24.42%
|
37.96
-7.18%
|
40.90
|
| Other Non Current Liabilities |
|
0.57
+0.00%
|
0.57
|
—
|
| Stockholders Equity |
|
207.29
+439.21%
|
-61.11
+13.47%
|
-70.62
|
| Common Stock Equity |
|
207.29
+439.21%
|
-61.11
+13.47%
|
-70.62
|
| Capital Stock |
|
0.02
|
—
|
—
|
| Common Stock |
|
0.02
|
—
|
—
|
| Share Issued |
|
15.51
+0.00%
|
15.51
+0.00%
|
15.51
|
| Ordinary Shares Number |
|
15.51
+0.00%
|
15.51
+0.00%
|
15.51
|
| Additional Paid In Capital |
|
207.27
|
—
|
—
|
| Total Equity Gross Minority Interest |
|
207.29
+439.21%
|
-61.11
+13.47%
|
-70.62
|
| Total Capitalization |
|
207.29
+439.21%
|
-61.11
+13.47%
|
-70.62
|
| Working Capital |
|
231.04
+977.86%
|
-26.32
+20.11%
|
-32.95
|
| Invested Capital |
|
207.29
+439.21%
|
-61.11
+13.47%
|
-70.62
|
| Total Debt |
|
3.67
-46.01%
|
6.80
-30.97%
|
9.85
|
| Capital Lease Obligations |
|
3.67
-46.01%
|
6.80
-30.97%
|
9.85
|
| Net Tangible Assets |
|
207.29
+439.21%
|
-61.11
+13.47%
|
-70.62
|
| Tangible Book Value |
|
207.29
+439.21%
|
-61.11
+13.47%
|
-70.62
|
| Other Equity Interest |
|
—
|
-61.11
+13.47%
|
-70.62
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Operating Cash Flow |
|
-41.13
-82.37%
|
-22.55
-139.99%
|
56.39
|
| Cash Flow From Continuing Operating Activities |
|
-41.13
-82.37%
|
-22.55
-139.99%
|
56.39
|
| Net Income From Continuing Operations |
|
-49.50
-97.04%
|
-25.12
-293.45%
|
-6.38
|
| Depreciation Amortization Depletion |
|
0.32
+87.79%
|
0.17
+24.64%
|
0.14
|
| Depreciation |
|
0.32
+87.79%
|
0.17
+24.64%
|
0.14
|
| Depreciation And Amortization |
|
0.32
+87.79%
|
0.17
+24.64%
|
0.14
|
| Other Non Cash Items |
|
0.57
+180.39%
|
0.20
|
—
|
| Stock Based Compensation |
|
7.68
+141.71%
|
3.18
+26.73%
|
2.51
|
| Deferred Tax |
|
-0.14
-101.19%
|
11.91
|
0.00
|
| Deferred Income Tax |
|
-0.14
-101.19%
|
11.91
|
0.00
|
| Operating Gains Losses |
|
0.14
-31.37%
|
0.20
+4.62%
|
0.20
|
| Gain Loss On Sale Of PPE |
|
0.14
|
0.00
-100.00%
|
0.20
|
| Change In Working Capital |
|
-0.20
+98.45%
|
-12.89
-121.51%
|
59.94
|
| Change In Receivables |
|
0.00
-100.00%
|
0.75
-45.82%
|
1.39
|
| Changes In Account Receivables |
|
0.00
-100.00%
|
0.75
-45.82%
|
1.39
|
| Change In Prepaid Assets |
|
-1.05
-178.31%
|
-0.38
-447.83%
|
-0.07
|
| Change In Payables And Accrued Expense |
|
14.18
+47363.33%
|
-0.03
+96.41%
|
-0.84
|
| Change In Accrued Expense |
|
10.45
+16429.69%
|
-0.06
+91.90%
|
-0.79
|
| Change In Payable |
|
3.73
+10864.71%
|
0.03
+173.91%
|
-0.05
|
| Change In Account Payable |
|
3.73
+10864.71%
|
0.03
+173.91%
|
-0.05
|
| Change In Other Working Capital |
|
-12.02
+12.96%
|
-13.81
-123.22%
|
59.45
|
| Change In Other Current Assets |
|
-1.31
|
0.00
|
—
|
| Change In Other Current Liabilities |
|
0.00
-100.00%
|
0.57
|
0.00
|
| Investing Cash Flow |
|
-1.45
-443.23%
|
-0.27
+16.88%
|
-0.32
|
| Cash Flow From Continuing Investing Activities |
|
-1.45
-443.23%
|
-0.27
+16.88%
|
-0.32
|
| Net PPE Purchase And Sale |
|
-1.45
-443.23%
|
-0.27
+16.88%
|
-0.32
|
| Purchase Of PPE |
|
-1.45
-443.23%
|
-0.27
+16.88%
|
-0.32
|
| Capital Expenditure |
|
-1.45
-443.23%
|
-0.27
+16.88%
|
-0.32
|
| Financing Cash Flow |
|
42.57
+86.57%
|
22.82
+140.70%
|
-56.07
|
| Cash Flow From Continuing Financing Activities |
|
42.57
+86.57%
|
22.82
+140.70%
|
-56.07
|
| Net Other Financing Charges |
|
42.57
+86.57%
|
22.82
+140.70%
|
-56.07
|
| Beginning Cash Position |
|
0.00
|
0.00
|
0.00
|
| End Cash Position |
|
0.00
|
0.00
|
0.00
|
| Free Cash Flow |
|
-42.57
-86.57%
|
-22.82
-140.70%
|
56.07
|
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|